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j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrUbiquitin Drug Discovery and DiagnosticsFundamentally, there are two questions everyone wants to know
about the ubiquitin pathway (yes, everyone!). How does it work,
and can we further exploit it for the beneﬁt of human health? Its
established role in fundamental cellular processes, and human pathol-
ogies like cancer and neurodegeneration forms the basis of both ques-
tions, and motivates interest in pursuing the answers. This special
issue of BBA provides reports from investigators engaged in either or
both lines of inquiry, and loosely serves as a summary of the recent
2011 Ubiquitin Drug Discovery and Diagnostics Conference (UDDD
2011), held in Philadelphia, PA. In this issue, you will read about as-
says being developed and used to screen E3's and DUBs (the positive
and negative regulatory machinery, respectively) in vitro for chemical
modiﬁers, as well as in vitro assays for the identiﬁcation of their cog-
nate substrates. Cell and tissue based assays particularly relevant to
neurological dysfunction are discussed, as are cellular responses to
DUB inhibition within the neurological context. Activity based suicide
inhibitor probes have proven useful in a variety of creative applica-
tions, which are reviewed here. The ubiquitin pathway does not oper-
ate in isolation, and aspects of its temporal regulation and interplay
with phosphorylation-based signaling are explored, as are functional
connections to the inﬂammatory response. The ability of cells to re-
ceive and interpret the information contained by multimer-linkages
of ubiquitin (“chains”) made through the various possible amines
(the N-terminus and seven lysines conserved in ubiquitin throughout
eukaryotes) is currently attracting a lot of interest. Here we will learn
about recent insights into various structures possible from among
chains of a single linkage (K48) and receptors speciﬁc to the “open”
conformation thereof; cellular receptors of a different (K63) linkage
signal are also described. Last but not the least are discussions about
the future of drug targeting- from the proteasome, to next generation
proteasomal inhibitors, to more selective pathway targets. Like UDDD
2011, we hope you ﬁnd this issue useful and stimulating to your scien-
tiﬁc interest in the ubiquitin pathway, whether basic or applied. And
like most people from investigators to patients, we hope that answers
to the ﬁrst question result in a rapid and resoundingly afﬁrmative an-
swer to the second.
Editor's note: Laura Sheard (26) and Kristopher Martin (33) were
killed 13 November 2011 when the car in which they were traveling
was struck from behind by an out-of-control driver experiencing a
psychotic episode. Laura was a 5th year graduate student at the Uni-0167-4889/$ – see front matter © 2012 Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.bbamcr.2012.09.006versity of Washington, in the laboratory of Dr. Ning Zheng. She was
scheduled to contribute an article to this issue, which is instead now
dedicated in entirety to her and Kristopher and all the coworkers,
friends, and family grieving their tragic loss.
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